GOG-3101 MK-2870-020 for cervical cancer - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is a safe and effective option for people with cervical cancer. We want to see how well it works compared to the standard treatment for this diagnosis.

¿Cuál es la Condición que se está estudiando?

Cáncer cervical

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
Have cancer that is metastatic (has spread) or has returned after treatment
Have received at least one previous line of treatment that included an anti-PD-1/anti-PD-L1 therapy

For more information about this study, contact the study team at patricia.vaudo@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 parts.

If you are in Part 1 of the study, you will take the study drug. If you are in Part 2 of the study, you will get another random assignment to 1 of 2 groups:

If you are in Group 1, you will take the study drug.
If you are in Group 2, you will receive the standard therapy that the study doctor believes is best for you. The standard drugs used to treat your form of cancer include: pemetrexed, tisotumab vedotin, topotecan, vinorelbine, gemcitabine, and irinotecan.

Detalles del Estudio

Título Completo

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Investigador Principal